Y101D
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 6, 2021 (NCT05028556)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06266143 | Phase 1/Phase 2 (Phase 2) | Feb 8, 2023 | Huazhong University of Science and Technology, Wuhan YZY Biopharma Co., Ltd. |
| NCT05028556 | Phase 1 | Aug 6, 2021 | Sun Yat-Sen University, Wuhan YZY Biopharma Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Wuhan YZY Biopharma Co., Ltd. | For profit | 2 | 2 | 2 | 2021 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1